Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
HIV Infections, Hepatitis C
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in patients naive for HIV and…
- Trial name
- NCT00437476
- Testing
- LPV/r, Nucleoside Reverse Transcriptase Inhibitors, PEG-IFNa 2a
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Hepatitis C, Chronic
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
This 3-arm study assessed the safety and efficacy of combination treatment with peginterferon alfa-2a + ribavirin in participants with chronic hepatitis C.
- Trial name
- NCT00800748
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 35 sites in Czechia, Slovakia
- Volunteers
- 372 people
- Sponsor
- Hoffmann-La Roche
Thrombocytopenia, Hepatitis C
Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C
This study will provide chronic hepatitis C patients with low platelets (less than 75x10^9/L) the opportunity to undergo treatment and possible cure of their virus.
- Trial name
- SQUELCH-C (NCT01821625)
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Chronic Hepatitis C
Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine
The objectives are 1. to determine the immunological profile (CD4+, CD8+ cells, DTH) induced by immunization with HCV antigen peptide vaccine with polyarginine. 2.
- Trial name
- NCT00602784
- Testing
- IC41
- Volunteers
- 66 people
- Sponsor
- Valneva Austria GmbH
Hepatitis C, Chronic
Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection
To assess the antiviral effect, safety and pharmacokinetics of rising doses of 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 150 mg, 200 mg, 300 mg, 450 mg, 650 mg, 900 mg oral BILB 1941 ZW administered Q8H in a polyethyleneglycol…
- Trial name
- NCT02254707
- Testing
- BILB 1941 ZW
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with chronic genotype 1 or 2 HCV infection who are…
- Trial name
- NCT02613871
- Testing
- LDV/SOF
- Where
- 8 sites in Taiwan
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Hepatitis C
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis…
- Trial name
- NCT00128271
- Testing
- Bavituximab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Peregrine Pharmaceuticals
Hepatitis C
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the efficacy of simeprevir in combination with sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of participants with sustained virologic response at…
- Trial name
- NCT02278419
- Testing
- Simeprevir, Sofosbuvir
- Where
- 2 sites in Egypt
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Hepatitis C
Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
The purpose of this study is to determine whether 24 week treatment with the Daclatasvir (DCV) in combination with Pegylated-interferon alfa 2a (pegIFNα-2a) and Ribavirin (RBV) is safe and demonstrates rate of Sustained Virologic…
- Trial name
- COMMAND-Asia (NCT01797848)
- Testing
- Peginterferon alfa 2a, Ribavirin, Daclatasvir
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
The primary objectives of this study are to evaluate safety, efficacy, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in adults on dialysis for end stage renal disease (ESRD) with chronic…
- Trial name
- SOF/VEL ESRD (NCT03036852)
- Testing
- SOF/VEL
- Where
- 22 sites in Australia, Canada and 4 more
- Volunteers
- 59 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis c
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients
Chronic hepatitis C virus infection affects an estimated one hundred and seventy million people around the world with and approximate prevalence 0.2-2 % in the United State of America and European countries.
- Trial name
- NCT03163849
- Testing
- Sofosbuvir , daclatasvir
- Where
- 2 sites in Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Hepatitis C, Chronic
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus…
- Trial name
- NCT01316237
- Testing
- GS-6620, GS-6620 tablet, 450 mg BID, GS-6620 tablet
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Gilead Sciences
End-Stage Renal Disease, Hepatitis C
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time.
- Trial name
- EXPANDER-1 (NCT02781649)
- Testing
- Zepatier, Ribavirin, Sofosbuvir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis C
Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection.
- Trial name
- NCT00629824
- Testing
- pegylated interferon alpha and plus ribavirin
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis B, Hepatitis C
Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India
This study will define the substantial disease burden associated with viral hepatitis in India, and provide a foundation to understand the host and viral determinants of disease pathogenesis that may ultimately impact treatment…
- Trial name
- NCT01772121
- Where
- 19 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Infection
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients
The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes 2 infection.
- Trial name
- NCT02482077
- Testing
- SOF+RBV, SOF+DCV, LDV/SOF
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Humanity and Health Research Centre
HCV
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve children weighing between 14 and 35 kg with…
- Trial name
- NCT05854511
- Testing
- Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Hepatitis C, Chronic
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
This observational long-term follow-up study will assess the persistence of direct acting antiviral (DAA) resistant mutations and the durability of sustained virological response in patients with chronic hepatitis C who have…
- Trial name
- NCT01168856
- Where
- 126 sites in United States, Australia and 13 more
- Volunteers
- 734 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 with or without ABT-333 and with or without ribavirin (RBV) in adult liver or renal transplant recipients with hepatitis C virus (HCV) genotype…
- Trial name
- CORAL-I (NCT01782495)
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, ribavirin
- Volunteers
- 129 people
- Sponsor
- AbbVie
Hepatitis C, Chronic, Hepatitis C
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PegIntron plus Rebetol combination therapy administered to patients with chronic hepatitis C.
- Trial name
- NCT00724230
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 505 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.